Detail akcie Anika Therapeut online

Business Summary: Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Anika Therapeutics Inc revenues decreased 1% to $119.9M. Net loss before extraordinary items increased from $3.4M to $8.8M. Revenues reflect United States segment decrease of 5% to $82.4M. Higher net loss reflects R& D increase of 21% to $23.9M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.23 to -$0.60.